[Journal logo]

Volume 68 
Part 1 
Pages o247-o248  
January 2012  

Received 14 December 2011
Accepted 19 December 2011
Online 23 December 2011

Key indicators
Single-crystal X-ray study
T = 100 K
Mean [sigma](C-C) = 0.002 Å
R = 0.051
wR = 0.126
Data-to-parameter ratio = 20.6
Details
Open access

Ethyl 2-(1,3-benzodioxol-5-yl)-1-[3-(1H-imidazol-1-yl)propyl]-1H-benzimidazole-5-carboxylate

aInstitute for Research in Molecular Medicine, Universiti Sains Malaysia, Minden 11800, Penang, Malaysia, and bSchool of Physics, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia
Correspondence e-mail: arazaki@usm.my

In the title compound, C23H22N4O4, the essentially planar [maximum deviation = 0.022 (1) Å] benzimidazole ring system forms dihedral angles of 86.16 (7) and 37.38 (6)°, respectively, with the imidazole and benzene rings. The dioxolane ring adopts an envelope conformation with the methylene C atom at the flap. In the crystal, C-H...O and C-H...N interactions link the molecules into a ribbon along the a axis. The crystal packing is further stabilized by weak [pi]-[pi] stacking interactions [centroid-centroid distances = 3.5954 (8) and 3.7134 (8) Å] and C-H...[pi] interactions.

Related literature

For the biological activity of benzimidazole derivatives, see: Grassmann et al. (2002[Grassmann, S., Sadek, B., Ligneau, X., Elz, S., Ganellin, C. R., Arrang, J. M., Schwartz, J. C., Stark, H. & Schunack, W. (2002). Eur. J. Pharm. Sci. 15, 367-378.]); Demirayak et al. (2002[Demirayak, S., Abu Mohsen, U. & Çaqri Karaburun, A. (2002). Eur. J. Med. Chem. 37, 255-260.]). For puckering parameters, see: Cremer & Pople (1975[Cremer, D. & Pople, J. A. (1975). J. Am. Chem. Soc. 97, 1354-1358.]). For stability of the temperature controller used in the data collection, see: Cosier & Glazer (1986[Cosier, J. & Glazer, A. M. (1986). J. Appl. Cryst. 19, 105-107.]). For a related structure, see: Yoon et al. (2011[Yoon, Y. K., Ali, M. A., Wei, A. C., Quah, C. K. & Fun, H.-K. (2011). Acta Cryst. E67, o2405.]).

[Scheme 1]

Experimental

Crystal data
  • C23H22N4O4

  • Mr = 418.45

  • Orthorhombic, P b c a

  • a = 15.8554 (2) Å

  • b = 15.3988 (2) Å

  • c = 16.2292 (2) Å

  • V = 3962.43 (9) Å3

  • Z = 8

  • Mo K[alpha] radiation

  • [mu] = 0.10 mm-1

  • T = 100 K

  • 0.42 × 0.28 × 0.20 mm

Data collection
  • Bruker SMART APEXII CCD area-detector diffractometer

  • Absorption correction: multi-scan (SADABS; Bruker, 2009[Bruker (2009). APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.]) Tmin = 0.960, Tmax = 0.981

  • 39067 measured reflections

  • 5782 independent reflections

  • 4429 reflections with I > 2[sigma](I)

  • Rint = 0.054

Refinement
  • R[F2 > 2[sigma](F2)] = 0.051

  • wR(F2) = 0.126

  • S = 1.06

  • 5782 reflections

  • 280 parameters

  • H-atom parameters constrained

  • [Delta][rho]max = 0.42 e Å-3

  • [Delta][rho]min = -0.26 e Å-3

Table 1
Hydrogen-bond geometry (Å, °)

Cg1 and Cg4 are the centroids of C11/C12/O3/C23/O4 and C1-C6 rings, respectively.

D-H...A D-H H...A D...A D-H...A
C2-H2A...O3i 0.95 2.48 3.3922 (17) 162
C15-H15B...O4ii 0.99 2.49 3.213 (2) 130
C23-H23A...N4iii 0.99 2.43 3.379 (2) 159
C10-H10A...Cg4iv 0.95 2.65 3.3005 (16) 126
C16-H16C...Cg1v 0.98 2.91 3.7282 (19) 142
Symmetry codes: (i) [x-{\script{1\over 2}}, y, -z+{\script{3\over 2}}]; (ii) x-1, y, z; (iii) -x+2, -y+2, -z+1; (iv) [-x, y+{\script{3\over 2}}, -z+{\script{3\over 2}}]; (v) -x+1, -y+2, -z+1.

Data collection: APEX2 (Bruker, 2009[Bruker (2009). APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.]); cell refinement: SAINT (Bruker, 2009[Bruker (2009). APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.]); data reduction: SAINT; program(s) used to solve structure: SHELXTL (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); program(s) used to refine structure: SHELXTL; molecular graphics: SHELXTL; software used to prepare material for publication: SHELXTL and PLATON (Spek, 2009[Spek, A. L. (2009). Acta Cryst. D65, 148-155.]).


Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: IS5032 ).


Acknowledgements

The authors thank the Malaysian Government and Universiti Sains Malaysia for the Research University Grants Nos. 1001/PFIZIK/811151 and (1001/PSK/8620012). The authors also wish to express their thanks to the Pharmacogenetic and Novel Therapeutic Research, Institute for Research in Molecular Medicine, Universiti of Sains Malaysia, Penang.

References

Bruker (2009). APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.
Cosier, J. & Glazer, A. M. (1986). J. Appl. Cryst. 19, 105-107.  [CrossRef] [ChemPort] [ISI] [details]
Cremer, D. & Pople, J. A. (1975). J. Am. Chem. Soc. 97, 1354-1358.  [CrossRef] [ChemPort] [ISI]
Demirayak, S., Abu Mohsen, U. & Çaqri Karaburun, A. (2002). Eur. J. Med. Chem. 37, 255-260.  [CrossRef] [PubMed] [ChemPort]
Grassmann, S., Sadek, B., Ligneau, X., Elz, S., Ganellin, C. R., Arrang, J. M., Schwartz, J. C., Stark, H. & Schunack, W. (2002). Eur. J. Pharm. Sci. 15, 367-378.  [ISI] [CrossRef] [PubMed] [ChemPort]
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.  [CrossRef] [details]
Spek, A. L. (2009). Acta Cryst. D65, 148-155.  [ISI] [CrossRef] [details]
Yoon, Y. K., Ali, M. A., Wei, A. C., Quah, C. K. & Fun, H.-K. (2011). Acta Cryst. E67, o2405.  [CSD] [CrossRef] [details]


Acta Cryst (2012). E68, o247-o248   [ doi:10.1107/S1600536811054572 ]

This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.